Citizens JMP Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL)

Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $443.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst commented, “Our physician survey confirms 1Q25 reimbursement seasonality with fewer patients on paid drug but projected long-term Rezdiffra use remains high and our first check on persistence is better than our modeled expectations; we reiterate our Market Outperform rating and $443 risk-adjusted, DCF-derived price target on Madrigal Pharmaceuticals.”

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $308.79 yesterday.

You May Also Be Interested In

• Citizens Upgrades Annexon Biosciences (ANNX) to Market Perform
• Spruce Biosciences (SPRB) PT Lowered to $144 at Citizens on Higher OpEx, Net Loss
• Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight